BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Interviews

From Data to Treatment: Medidata's Fareed Melhem Discusses AI's Impact on Clinical Trials

by Andrii Buvailo, PhD  (contributor )   •   Oct. 29, 2023  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Clinical Trials   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

As the potential of artificial intelligence (AI) continues to unfold, how is it revolutionizing the intricate landscape of clinical trials? How can vast reservoirs of data be harnessed to enhance patient experiences and accelerate drug discovery? Navigating the maze of global regulations presents its own challenges, but can these be surmounted with technological innovation? And in an era that emphasizes the importance of diversity and inclusion, how can we ensure that clinical trials truly reflect the diverse populations they serve?

In order to answer these and some other questions regarding the growing role of AI in clinical trials, I have talked to Fareed Melhem, Senior VP and Head of AI at Medidata, a Dassault Systèmes company.

Medidata, a provider of clinical trial solutions to the life sciences industry, recently announced a multi-year partnership expansion with Catalyst Clinical Research to support their global oncology brand, Catalyst Oncology. Through this extended partnership, Catalyst can continue to support over 150 oncology studies and manage more than 80 next-generation cancer clinical trials today across Phase I-III. Notably, around 90% of all oncology FDA approvals last year were developed using Medidata software.

#advertisement
AI in Drug Discovery Report 2025

Continue reading

This content available exclusively for BPT Mebmers

 BPT Membership 

Topics: Clinical Trials   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.